Related Experiment Video
Updated: Aug 5, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
[Research Progress of CDK Inhibitors in Acute Myeloid Leukemia --Review]
Yi-Fan Liu1,2, Hui Liu1
1Department of Hematology, Beijing Hospital; National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100005, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
|August 3, 2026
Summary
Cyclin-dependent kinase (CDK) inhibitors show promise for treating acute myeloid leukemia (AML). Research reviews CDK inhibitor progress, challenges like toxicity, and strategies to improve AML treatment outcomes.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute myeloid leukemia (AML) is a complex cancer characterized by heterogeneity, leading to treatment resistance and poor prognosis.
- Aberrant cyclin-dependent kinases (CDKs) are key drivers of AML progression, impacting cell cycle and transcription.
- Current AML treatments face limitations due to drug resistance and patient relapse.
Purpose of the Study:
- To systematically review the therapeutic potential of CDK inhibitors in AML treatment.
- To analyze preclinical and clinical data for CDK inhibitors targeting CDKs like CDK2, CDK4/6, CDK7, and CDK9.
- To discuss current limitations and explore strategies for optimizing CDK inhibitor therapy in AML.
Main Methods:
- Systematic literature review of preclinical studies and clinical trials.
- Focus on research investigating CDK inhibitors for AML treatment.
- Analysis of specific CDK targets (CDK2, CDK4/6, CDK7, CDK9) in AML.
Main Results:
- CDK inhibitors demonstrate promising anti-AML activity in preclinical and early clinical settings.
- Targeting specific CDKs (e.g., CDK2, CDK4/6, CDK7, CDK9) is a key strategy in AML drug development.
- Challenges include off-target effects and systemic toxicity, impacting therapeutic efficacy.
Conclusions:
- CDK inhibitors represent a potential therapeutic avenue for AML, addressing disease heterogeneity.
- Overcoming challenges like toxicity and resistance is crucial for successful clinical application.
- Further research and optimized strategies are needed to enhance CDK inhibitor efficacy in AML treatment regimens.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.